Fox, Elizabeth <br/><br/>
Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621).  [electronic resource] 

 -  Pediatric blood & cancer  Jun 2014 
 - 990-6 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1545-5017 
<br/><br/><label>Standard No.: </label>10.1002/pbc.24900  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Antineoplastic Agents--adverse effects<br/>Biomarkers<br/>Capsules<br/>Child<br/>Child, Preschool<br/>Combined Modality Therapy<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Gastrointestinal Diseases--chemically induced<br/>Hematologic Diseases--chemically induced<br/>Humans<br/>Male<br/>Nervous System Diseases--chemically induced<br/>Neuroblastoma--drug therapy<br/>Quality of Life<br/>Recurrence<br/>Salvage Therapy<br/>Sulfonamides--adverse effects<br/>Suspensions<br/>Treatment Failure<br/>Tubulin Modulators--therapeutic use